These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22220214)

  • 1. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.
    Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM
    PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotrafficking of SV2 and synaptotagmin at the synapse.
    Yao J; Nowack A; Kensel-Hammes P; Gardner RG; Bajjalieh SM
    J Neurosci; 2010 Apr; 30(16):5569-78. PubMed ID: 20410110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SV2 regulates neurotransmitter release via multiple mechanisms.
    Nowack A; Yao J; Custer KL; Bajjalieh SM
    Am J Physiol Cell Physiol; 2010 Nov; 299(5):C960-7. PubMed ID: 20702688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin.
    Schivell AE; Batchelor RH; Bajjalieh SM
    J Biol Chem; 1996 Nov; 271(44):27770-5. PubMed ID: 8910372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.
    Stahl SM
    J Clin Psychiatry; 2004 Sep; 65(9):1162-3. PubMed ID: 15367040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SV2A and SV2C contain a unique synaptotagmin-binding site.
    Schivell AE; Mochida S; Kensel-Hammes P; Custer KL; Bajjalieh SM
    Mol Cell Neurosci; 2005 May; 29(1):56-64. PubMed ID: 15866046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.
    Madeo M; Kovács AD; Pearce DA
    J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis.
    Chang WP; Südhof TC
    J Neurosci; 2009 Jan; 29(4):883-97. PubMed ID: 19176798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking.
    García-Pérez E; Mahfooz K; Covita J; Zandueta A; Wesseling JF
    Epilepsia; 2015 Apr; 56(4):535-45. PubMed ID: 25684406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SV2 is the protein receptor for botulinum neurotoxin A.
    Dong M; Yeh F; Tepp WH; Dean C; Johnson EA; Janz R; Chapman ER
    Science; 2006 Apr; 312(5773):592-6. PubMed ID: 16543415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
    Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
    J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes.
    Matveeva EA; Vanaman TC; Whiteheart SW; Slevin JT
    Epilepsia; 2008 Oct; 49(10):1749-58. PubMed ID: 18513349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SV2 mediates entry of tetanus neurotoxin into central neurons.
    Yeh FL; Dong M; Yao J; Tepp WH; Lin G; Johnson EA; Chapman ER
    PLoS Pathog; 2010 Nov; 6(11):e1001207. PubMed ID: 21124874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam.
    Boido D; Farisello P; Cesca F; Ferrea E; Valtorta F; Benfenati F; Baldelli P
    Neuroscience; 2010 Nov; 171(1):268-83. PubMed ID: 20804820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.